Ovarian Cancer Antibody Therapeutic

Background

• Occurring primarily in post-menopausal women, epithelial ovarian carcinoma (EOC) is typically diagnosed at late stages resulting in a high recurrence rate and a low five-year overall survival rate.
• The anti-Mullerian hormone receptor II (AMHR2) is expressed in most EOC.
• AMHR2 is normally expressed in ovarian tissue but turned off in postmenopausal ovaries.

Technology Overview

• Cleveland Clinic has developed a monoclonal antibody against AMHR2.
• Vaccination against AMHR2-ED has demonstrated inhibition of the growth of murine EOCs through CD4+ T- cells that facilitate B-cells to produce AMHR2ED-specific IgG.
• A panel for AMHR2-ED was developed to find an antibody that would mimic the clinical effectiveness of the polyclonal IgG response resulting from AMHR2ED vaccination.
• Treatment with the humanized AMHR2-ED antibody demonstrated apoptosis in EOCs.

Further details:

Immunotherapy of ovarian cancer with a monoclonal antibody specific for the extracellular domain of anti-Müllerian hormone receptor II. Oncotarget. 2020 May 19;11(20):1894-1910. doi: 10.18632/oncotarget.27585.

Primary Immunoprevention of Epithelial Ovarian Carcinoma by Vaccination against the Extracellular Domain of Anti-Müllerian Hormone Receptor II. Cancer Prev Res (Phila). 2017 Nov;10(11):612-624. doi: 10.1158/1940-6207.CAPR-17-0154.

Stage of Development

In vivo preclinical proof of concept established; humanized antibody.

Applications

• Can be used as a naked antibody or in an antibody-drug conjugate.